Compare BEEM & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | EVAX |
|---|---|---|
| Founded | 2006 | 2008 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 25.9M |
| IPO Year | 2018 | 2020 |
| Metric | BEEM | EVAX |
|---|---|---|
| Price | $1.40 | $2.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $3.50 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 1.4M | 194.5K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.77 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,236,000.00 | N/A |
| Revenue This Year | $40.48 | N/A |
| Revenue Next Year | $32.17 | $328.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.97 | $2.52 |
| 52 Week High | $4.04 | $12.15 |
| Indicator | BEEM | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.63 | 43.85 |
| Support Level | $1.38 | $2.91 |
| Resistance Level | $1.42 | $3.62 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 47.01 | 20.99 |
Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.